Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:45 pm Sale |
2022-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
RA Capital Management, L.P. | 0 0.000% |
-2,850,000 (Position Closed) |
Filing History |
| 2023-02-14 3:01 pm Sale |
2022-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rock Springs Capital Management LP | 0 0.000% |
-2,581,299 (Position Closed) |
Filing History |
| 2023-02-14 2:26 pm Sale |
2022-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Avidity Partners Management LP | 2,040,000 4.100% |
-2,365,000 (-53.69%) |
Filing History |
| 2023-02-06 3:02 pm Sale |
2022-12-30 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 0 0.000% |
-2,869,650 (Position Closed) |
Filing History |
| 2022-11-04 4:42 pm Sale |
2022-11-03 | 13D | PhaseBio Pharmaceuticals, Inc. PHASQ |
New Enterprise Associates 13, L.P. | 0 0.000% |
-6,641,634 (Position Closed) |
Filing History |
| 2022-07-19 11:30 am Purchase |
2022-07-12 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
MAI Capital Management | 2,675,376 5.800% |
2,675,376 (New Position) |
Filing History |
| 2022-02-14 6:24 pm Purchase |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rock Springs Capital Management LP | 2,581,299 5.370% |
1,266,925 (+96.39%) |
Filing History |
| 2022-02-14 4:12 pm Sale |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rosalind Advisors, Inc. | 707,467 1.500% |
-1,900,390 (-72.87%) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
RA Capital Management, L.P. | 2,850,000 5.900% |
0 (Unchanged) |
Filing History |
| 2022-02-11 7:52 pm Purchase |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Avidity Partners Management LP | 4,405,000 9.200% |
120,000 (+2.80%) |
Filing History |
| 2022-02-04 09:29 am Purchase |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 2,869,650 5.970% |
944,570 (+49.07%) |
Filing History |
| 2022-02-01 2:42 pm Unchanged |
2021-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
JOHNSON & JOHNSON JNJ |
1,607,044 3.300% |
0 (Unchanged) |
Filing History |
| 2021-11-10 08:51 am Sale |
2021-10-29 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 1,925,080 4.010% |
-4,089,809 (-67.99%) |
Filing History |
| 2021-08-10 07:57 am Purchase |
2021-07-30 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 6,014,889 12.540% |
4,447,233 (+283.69%) |
Filing History |
| 2021-05-19 2:25 pm Purchase |
2021-05-12 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rosalind Advisors, Inc. | 2,607,857 5.400% |
2,607,857 (New Position) |
Filing History |
| 2021-03-24 4:30 pm Purchase |
2021-03-18 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
RA Capital Management, L.P. | 2,850,000 6.000% |
2,850,000 (New Position) |
Filing History |
| 2021-03-22 4:05 pm Purchase |
2021-03-18 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Avidity Partners Management LP | 4,285,000 9.400% |
4,285,000 (New Position) |
Filing History |
| 2021-02-16 4:32 pm Sale |
2020-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rock Springs Capital Management LP | 1,314,374 4.480% |
-337,500 (-20.43%) |
Filing History |
| 2021-01-11 09:10 am Sale |
2020-12-31 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
WELLINGTON MANAGEMENT CO LLP | 1,567,656 5.340% |
-2,324,600 (-59.72%) |
Filing History |
| 2020-11-16 4:59 pm Purchase |
2020-11-06 | 13G | PhaseBio Pharmaceuticals, Inc. PHASQ |
Rock Springs Capital Management LP | 1,651,874 5.630% |
526,874 (+46.83%) |
Filing History |